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ABSTRACT:
Coronary heart disease is the single most frequent cause of mortality in Western
countries. Up to 30% of patients surviving an acute coronary syndrome (ACS) will experience
a recurrent event within 5 years. Yet precisely defining which of these patients will go on to
experience a recurrent event remains difficult despite the use of contemporary risk scores, such
as the SYNTAX (Synergy between Percutaneous Coronary Intervention with TAXUS and
Cardiac Surgery) and GRACE (Global Registry of Acute Coronary Events) scores. Given the
important role of computed tomography coronary angiography (CTCA) in defining risk in the
low to intermediate risk coronary heart disease cohort, there may be a role for CTCA in better
defining risk in higher risk individuals, such as those having suffered ACS. Accurately
quantifying total plaque burden and its components (i.e. low attenuation plaque) may provide
additional benefit to currently used methods and provide a more accurate measure of risk for
these at-risk patients.
This thesis demonstrates that CTCA-derived residual plaque burden and plaque
components correlate with risk scores (GRACE and SYNTAX scores) validated as predictors
of cardiovascular events and death in individuals following an ACS, providing promising data
that suggests CTCA could yet have a role in improving risk stratification in the post-ACS
cohort. However, further studies directly comparing CTCA-derived coronary plaque burden
with conventional risk stratification models, such as the GRACE and SYNTAX scores, are
required to demonstrate any incremental benefit in prognostication for this patient group.
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CHAPTER ONE - INTRODUCTION

Coronary heart disease (CHD) is the most frequent cause of mortality in Western countries1,
accounting for approximately one-fifth of all deaths.2-6 Recently, it has become the single most
common cause of death in low, and middle, as well as high income countries.7 Approximately
one-quarter to one-half of all cardiovascular events occur in individuals with established CHD,
who account for only 6% of the general population.8-10 Furthermore, 15-30% of patients
surviving an acute coronary syndrome (ACS) event will experience a recurrent event within
five years, often with a significant mortality rate.8, 11
Focus on modifiable risk factors such as smoking, hypertension, low-density
lipoprotein (LDL) cholesterol, diabetes and obesity have been important in decreasing
cardiovascular events and form the basis of clinical practice guidelines on prevention.12-15
However, control of risk factors alone does not address the significant heterogeneity among
individuals who may have future cardiovascular events. In particular, the post-ACS cohort has
a heterogeneous risk profile,16 and accurately defining individual patient risk is necessary to
inform on the appropriate medical therapy and/or intervention. Novel methods are required to
identify specific markers that characterise an individual at increased risk. Recent focus on
coronary plaque quantification and morphology suggest an important role in defining risk and
is the subject of this thesis.17
Current evaluation of patients with suspected ACS involves the use of biomarkers (i.e.
high sensitivity cardiac troponin [hs-cTn]) to identify those at high-risk. Those at high-risk
usually undergo invasive coronary angiography (ICA) to confirm or exclude significant
coronary luminal stenosis, with subsequent percutaneous coronary intervention (PCI) if
deemed appropriate. However, out of those with suspected ACS referred for ICA, 10-28% have
only mild coronary artery disease (CAD) or normal coronary arteries, and up to 45% do not
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require revascularisation.18-21 Furthermore, while ICA provides good assessment of luminal
patency, it provides little information regarding the vessel wall. Computed Tomography
Coronary Angiography (CTCA), although providing inferior assessment of luminal patency,
allows for the quantification of plaque burden and the identification of high-risk plaque (HRP)
characteristics in the vessel wall.22 The presence of these features may identify patients at a
higher risk, allowing for improved risk stratification and prognostication. Indeed, recent
research suggests that CTCA may have an important role in the risk stratification of low and
intermediate cardiovascular risk patients, due to its ability to identify important features of the
vessel wall in addition to luminal patency.17, 23-26 Furthermore, CTCA may have a role in
clarifying diagnosis in patients with myocardial infarction with non-obstructive coronary
arteries (MINOCA) and could theoretically minimise the need for invasive coronary
angiography in certain lower risk ACS patients.

Pathophysiology of the Acute Coronary Syndrome
An acute coronary syndrome refers to atheromatous plaque rupture or erosion with associated
intraluminal thrombus within the coronary arterial tree, resulting in subsequent myocardial
ischaemia and infarction.27, 28 Of those with ACS, patients with at least two contiguous leads
with ST-segment elevation ≥2.5mm in men < 40 years, ≥2mm in men ≥40 years, or ≥1.5mm
in women in leads V2–V3 and/or ≥ 1mm in the other leads are defined as having a STEMI
(ST-Elevation Myocardial Infarction), while those with not fulfilling these criteria are defined
as having NSTEMI (Non ST-Elevation Myocardial Infarction) or Unstable Angina (UA).29
NSTEMI is differentiated from UA through the measurement of cardiac troponins greater than
the 99th percentile upper reference limit.28
Understanding of the pathological mechanisms underlying the acute coronary
syndrome has advanced significantly over recent decades. Histo-pathological studies have
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demonstrated that the most common cause of ACS is plaque rupture of a thin-capped
fibroatheroma (TCFA), in which a disruption of the fibrous cap exposes the underlying necrotic
core, resulting in luminal thrombus formation.30, 31 When the initial thrombotic event causes
complete or near-complete occlusion of the epicardial coronary vessel, an occlusive myocardial
infarction is said to occur. Occlusive myocardial infarction usually manifests clinically as a
STEMI, whereas non-occlusive myocardial infarction is more likely to present clinically as a
NSTEMI. Angiographic findings have demonstrated that the culprit lesion for STEMI is
typically non-obstructive prior to the thrombotic event. Typically, plaque rupture occurs in
lesions demonstrating <50% luminal stenosis32 usually at the cap margin or shoulder region.33
TCFAs are most commonly seen in the proximal third of the major coronary arteries,34 usually
at or near a bifurcation,35 where there is exposure to disturbed flow or lower endothelial shear
stress.36 These segments of the coronary arteries represent the locations where CTCA has the
highest image quality and accuracy for the detection of plaque.37
Plaque rupture of a TCFA is the most frequent cause of thrombosis38 and has been
shown to account for approximately 79% of fatal myocardial infarctions, with plaque erosion
and thrombosis of a calcified nodule thought to account for the remaining events.39, 40 The
TCFA is characterised by a necrotic core, with a fibrous cap <65μm in 95% of lesions, scant
smooth muscle cells and abundant macrophages, similar in composition to ruptured plaque.41
Plaque associated with a TCFA has a mean necrotic core length of 8mm and an area of >1mm2
in approximately 80% of cases, dimensions which are greater than the detection threshold of
modern CTCA scanners (>1mm).42 In contrast to plaque rupture, lesions associated with plaque
erosion are rich in proteoglycans and smooth muscle cells, typically devoid of a necrotic core.
Thrombus formation occurs due to direct contact of blood products with the tunica intima, in
an area of the plaque devoid of endothelium.41 The risk factors for plaque erosion appear to
differ significantly from those associated with rupture and remain poorly defined. While the
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pathogenesis remains unknown, coronary vasospasm is suspected to play a key role.31 The least
common lesion, the calcified nodule, results in irregularity of the surface of the fibrous cap and
lacks endothelial cells, predisposing to thrombus formation, typically in tortuous and calcified
arteries of older individuals.31, 43
The concept of the vulnerable plaque has previously been used to define a identifiable
precursor lesion that is at a high risk for disruption or thrombosis35, including TCFA,
pathological intimal thickening, thick-capped fibroatheroma and calcified plaque with calcified
nodules.41 However, this model has been challenged, with many authors now insisting that the
focus should remain on the atherosclerotic disease burden rather than features of individual
plaques.44, 45 Recent evidence has demonstrated the presence of HRP may have more of a role
in identifying patients at risk, rather than specific target lesions at risk.46

Figure 1.1: Features of high-risk vs low risk plaque
Stable plaque is characterised by a thick, fibrous cap with minimal lipid volume, whereas unstable high-risk plaque
has a large volume necrotic core and thin fibrous crap.
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Pathophysiological basis of coronary plaque burden as an important predictor of future
cardiovascular events
Previously, rather than the direct quantification of coronary plaque burden, the major focus of
coronary imaging research was the identification of the ‘vulnerable plaque’, a specific
atherosclerotic lesion prone to rupture and characterized by certain high-risk features.47 It was
hoped that the pre-emptive treatment of such lesions, for example with PCI, would reduce
cardiovascular events and associated mortality. However, several previous meta-analyses
failed to demonstrate a reduction in cardiovascular events or death with lesion-specific
intervention in those with stable coronary artery disease when compared to treatment with
medical therapy alone.48, 49 These findings were recently confirmed in a major contemporary
randomised control trial of over 5000 individuals with stable coronary artery disease.50 From a
pathophysiological perspective, the failure to improve outcomes by intervening on a specific
high-risk lesion is perhaps unsurprising, given that many plaque rupture events are
subclinical31, 51 and that after 12 months, the majority of high-risk low attenuation plaques
become lower risk fibrotic plaque or thick-capped fibroatheroma.52 However, despite this,
numerous studies utilizing a variety of imaging modalities (including CTCA, intravascular
ultrasound [IVUS] and optical coherence tomography [OCT]) have demonstrated the
independent and incremental prognostic value of the identification of HRP features.45, 53-55
Nonetheless, because these studies did not consider total coronary plaque burden as a potential
confounding factor, it is possible that the presence of HRP characteristics simply serve as a
surrogate of a more widespread, metabolically active atherosclerotic process.
Contrary to imaging strategies attempting to identify specific vulnerable plaques, the
measurement of total coronary plaque burden provides a direct estimation of the diffuse,
systemic atherosclerotic disease process. Indeed, the most important predictors of future ACS
events are the extent and activity of coronary plaque burden and risk factors for an
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inflammatory and prothrombotic environment.44,

56, 57

Direct quantification of plaque

components, such as higher-risk low attenuation plaque burden, may provide an even closer
estimate of a metabolically active, aggressive phenotype of atherosclerosis, of which there is a
higher chance of plaque rupture occurring and coinciding with the necessary prothrombotic
conditions.58 However, precise and accurate prediction of future cardiovascular events remains
difficult, as the total burden of atherosclerosis, plaque composition, plaque location, systemic
inflammation, neurohormonal dysregulation and thrombogenicity must converge to create a
“perfect storm scenario”, where arterial narrowing and subsequent myocardial ischaemia can
occur.59, 60
For patients following an ACS event, quantifying the magnitude and activity of
coronary plaque burden may be even more important when compared to those without a history
of coronary events, as these individuals are more likely to have the pro-thrombotic and
inflammatory characteristics necessary for an acute plaque rupture to become clinically
significant. Nonetheless, the accurate estimation of total coronary plaque burden and plaque
composition remains only one factor, albeit quantifiable and important, in determining whether
a future ACS event will occur.

Basic Principles of CT Imaging
CT scanners utilize an x-ray tube and detectors mounted on opposing sides of a gantry that
continuously rotate around a patient, with images acquired as the patient moves through the
gantry.61 The transmitted intensity of the x-ray beam decreases exponentially as it traverses the
patient, with this decrease varying based on the penetrating characteristics of the x-ray beam
and physical characteristics of the specific tissue.62 The data acquisition system converts the
raw data from the CT scan detector to produce images composed of voxels of varying shades
of grey, based on the mean attenuation of the tissue within a given voxel.61 Attenuation is the
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reduction of the intensity of an x-ray beam as it traverses matter. This reduction may be caused
by either absorption or deflection and can be quantified by the linear attenuation coefficient,
the fractional change in x-ray intensity per thickness of the attenuating material.62 Attenuation
on CT imaging is quantified by Hounsfield Units (HU), which are defined as linear
transformations of measured attenuation coefficients of a material with reference to water.63
White areas typically represent regions of high attenuation (high HU values), while darker
areas represent regions of lower attenuation (lower HU values).61, 62 Modern multiple-row
detector CT (MDCT) enables the acquisition of three-dimensional cardiac images with high
spatial and temporal resolution, with an array of x-ray detectors that encompass a greater area,
while collecting data from multiple slices for each rotation of the scanner.61, 64

Coronary artery stenosis
Coronary artery stenosis is a reduction in arterial luminal diameter typically occurring as a
result of the progression of coronary atherosclerosis. It may occur secondary to continual
plaque growth of a positively remodelled vessel segment, or due to shrinkage of a particular
vessel segment.31 The earliest progressive atherosclerotic lesion is that of pathological intimal
thickening, characterised by layers of smooth muscle cells in a proteoglycan-collagen matrix
with an underlying lipid pool and a variable number of macrophages on the luminal aspect of
the plaque. Plasma lipoproteins, especially LDL, aggregate and bind to proteoglycans located
within the extracellular matrix of the lipid pool.65 Pathological intimal thickening may
eventually progress to fibroatheroma, characterised by the presence of an acellular necrotic
core composed of cellular debris devoid of extracellular matrix and apoptotic macrophages.
This necrotic core is typically covered by a thick fibrous cap composed of smooth muscle cells
within a proteoglycan-collagen extracellular matrix. The fibrous cap is critical in determining
the stability and integrity of the fibroatheroma, and with the progression of disease may thin
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forming a TCFA.65 Frequently, the initial accumulation of atherosclerotic plaque manifests as
an increase in vessel size without a reduction in luminal diameter, known as positive
remodelling.66 This compensatory enlargement may delay luminal stenosis until plaque burden
is >40%66 and is associated with increasing lipid content, macrophage infiltration and plaque
vulnerability.67 In contrast, negative remodelling, defined as a reduction in vessel size, is
associated with fibrous tissue and few inflammatory cells. It is seen more commonly in chronic
total occlusions and in lesions associated with plaque erosion.67
Many published studies have demonstrated the excellent negative predictive value
(typically greater than 99%) of CTCA in symptomatic patients.24, 68-73 The utilisation of newer
CT technology, such as 320-segment, 256 slice and dual-source CT scanners, has confirmed
the high negative predictive value of CTCA for ruling out anatomically significant coronary
artery disease.74-76 A meta-analysis of 54 studies77 demonstrated an increase in the sensitivity
for the detection of >50% obstructive stenosis with 64-slice CT scanners compared with a 16slice CT scanners (93% vs 83%). Significant reductions in motion78 and calcium artefacts have
played important roles in this improvement. In a systematic review of 22 studies examining the
accuracy of dual-source CT for detection of arterial stenosis in difficult to image patient groups,
Westwood et al.79 reported a pooled, per-patient estimate of sensitivity of 97.7% and 97.7%
and specificity of 81.7% and 86.3%, for patients with arrhythmias and high heart rates
respectively.
Several studies have suggested that significant coronary artery stenosis predicts worse
cardiovascular outcomes.24, 80 For example, in a retrospective analysis of a large, multicentre
observational study of 15,187 patients without prior known CAD who were referred by a
physician for CTCA, those with obstructive CAD (>50% stenosis) were more likely to
experience major adverse cardiovascular events (MACE) when compared with patients with a
normal CTCA at a mean of 2.4 (±1.2) years follow-up (HR: 11.21, p<0.001).81 Similar findings
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were seen in two single-centre consecutive cohort studies: In a study of 1,127 patients, Min et
al.82 demonstrated that moderate (>50%) or severe (>70%) coronary stenosis (per segment) on
CTCA predicted increased all-cause mortality (risk-adjusted HR: 1.05 (95% CI: 1.02–1.09),
p<0.01) at a mean follow-up of 15.3 (3.9) months. In a study of 1,304 patients investigated for
suspected CAD,83 cumulative event-free survival was 54% for hard events and 31% for all
events in patients with obstructive CAD (>50% stenosis) on CTCA at a mean of 52 (± 22)
months of follow-up.
A meta-analysis84 of 33 studies comparing CTCA with IVUS, including a total of 946
patients, demonstrated that the percent area stenosis of coronary arteries was comparable
between CT and IVUS (weighted mean difference -1.8%, 95% CI -4.10 to 0.49, p<0.12).
However, multiple studies85-88 have demonstrated that while CTCA correlates well with
quantitative ICA and IVUS in terms of percent maximal diameter stenosis, it does so with a
relatively large standard deviation, typically to within 25% of the mean percent maximal
diameter stenosis of ICA (with a 95% CI) at best. CTCA has a tendency to overestimate the
degree of stenosis, at least in part because of partial volume effects that lead to the amplification
of the size of high attenuation components such as calcified plaque.78, 84 Extensive calcification
frequently leads to overestimation or paradoxical underestimation of coronary artery stenosis
severity.89 Furthermore, the limited spatial resolution of CTCA compared to ICA remains a
significant limitation when comparing these imaging modalities.90 Therefore, CTCA is
typically utilised for ruling out coronary artery disease rather than accurately determining the
degree of coronary stenosis and the need for intervention.

Coronary plaque burden
Total burden of atherosclerosis is a major determinant of cardiovascular disease (CVD) risk
and can be assessed by coronary CT, providing incremental prognostication over and above
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calcium quantification and the non-invasive identification of luminal narrowing.91 In an exvivo heart model, Knollman et al.92 demonstrated a significant correlation between the total
plaque area measured by CTCA and findings on histology. Small studies have demonstrated
that segmental plaque burden on CTCA is highly correlated with plaque burden identified by
IVUS.93-95 It has been estimated that CTCA detects approximately two times the number of
atherosclerotic lesions as ICA.96 The risk of future coronary events increases with the extent
of atherosclerotic disease burden, presumably because there is an increased chance of an
individual plaque rupturing, resulting in a thrombotic event.44, 97 Alternatively, a greater plaque
burden may be indicative of a more rapidly progressive, virulent atherosclerotic process.
Figure 3 and Table 1 below demonstrate the numerous studies that have consistently
reported an association between increasing plaque burden and mortality/MACE in patients
investigated for suspected CAD. This association is seen despite the heterogeneity in defining
and quantifying plaque burden within the literature. Plaque burden is most often calculated by
the following equation:98 (Vessel Area−Lumen Area)/Vessel area×100. However, many
different scoring systems for the quantification of plaque burden have been described. For
example, Min et al.82 described the segment involvement score (SIS) and segment stenosis
score (SSS) to objectively quantify plaque burden, demonstrating an increase in risk-adjusted
all-cause mortality with increasing scores. Other studies using the SIS and SSS reported similar
associations.24, 83, 99 However, there are important limitations of these scoring systems which
must be considered, including a failure to account for the anatomical distribution of
atherosclerosis and the assumption that all plaque burden is additive, regardless of lesion
location. For example, results from the CONFIRM80 (COronary CT Angiography EvaluatioN
For Clinical Outcomes: An InteRnational Multicenter Registry) registry demonstrate these
limitations, where it was shown that proximal segmental involvement has a larger influence on
clinical outcomes than distal segmental involvement. Other described scoring systems include
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the three-vessel score,82, 83 the Duke CAD index,82, 86 the CT SYNTAX score100, 101 and the
CTA-adapted Leaman score.102-104 Thus far, no single scoring method has been proven as
superior with few studies comparing these scores directly.
Two previous studies have examined the relationship between plaque burden or volume
and prognosis in patients following an ACS event. In a study of 312 consecutive patients
presenting with NSTEMI who underwent CTCA prior to ICA, over a median follow-up of 16
months, it was demonstrated that total non-calcified plaque volume (defined as any plaque
<130 HU) in nonobstructive lesions was independently associated with cardiac events
(HR=1.18 / 100mm3 plaque volume increase, 95% CI=1.06-1.31, p=0.01).105 Further
characterisation of plaque composition (i.e. LAP) was not reported. In another study of 169
patients with NSTEMI, residual plaque burden index (defined as total plaque volume divided
by vessel length, excluding stented coronary segments) was significantly associated with
MACE at a median follow-up of 4.8 years (HR=1.22, 95% CI = 1.01-1.48, p=0.04). However,
no characterisation of plaque composition was reported. Increasing plaque burden on CTCA
has also been demonstrated to improve the prediction of future cardiovascular events and
mortality beyond that of stenosis severity and clinical risk scores in the low-to-intermediate
cardiovascular risk population.73, 106, 107 In low CV risk populations, extensive non-obstructive
CAD on CTCA identifies patients with CVD event rates similar to those with obstructive single
vessel disease.106, 108 The presence of any non-obstructive CAD predicts CVD event rates 2 to
4.5 fold higher than those without identifiable CAD.106, 109, 110 Furthermore, several studies
have demonstrated that the quantification of plaque burden composition, specifically the
quantification of LAP burden, provides the most robust prognostication of the low to
intermediate CVD risk population.58, 111 Further studies are required to determine the value of
the quantification of plaque burden composition in the post-ACS cohort.
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In the future, the automation of the quantification of plaque burden will likely improve
the reproducibility, accuracy and efficiency of CTCA imaging analysis.42 A prospective
study112 of 1650 patients demonstrated that semi-automated plaque quantification (reporting
volumetric and geometric plaque properties) provides incremental prognostic value over
Framingham Risk Score (FRS) and conventional CTCA reading (area under the ROC curve
(AUC) of 0.79 vs 0.64, p <0.05). Other studies using alternative or the same software for
quantification also reported that plaque volume assessment predicts future clinical outcomes
in patients with stable coronary artery disease, beyond that of conventional coronary CTA
analysis.111, 113

Figure 1.3: Hazard ratios for all-cause mortality and MACE according to different plaque burden scoring
parameters
Numerous studies have demonstrated the prognostic utility of plaque burden quantification for the prediction of
cardiovascular events and mortality in the stable coronary artery disease population.

CI = confidence interval, HR = hazard ratio, MACE = major adverse cardiovascular events
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Table 1.1: Hazard ratios for mortality and MACE according to different plaque burden scoring parameters
First author,

Study Design

Year published
Min et al82,

Retrospective

Sample

Plaque Burden Scoring

Size

Parameter

1127

2007
Andreini et al83,

SIS (per segment

Clinical Outcome

Hazard

95% CI

Ratio
All-cause mortality

1.16

1.05 – 1.28

Hard Cardiac Events

1.38

1.31 – 1.47

All-cause mortality

1.22

1.03 – 1.44

Extensive (SIS>4)

Cardiovascular death

3.1

1.5 – 6.4

nonobstructive CAD

or MI

SIS (per segment

MACE (death, MI,

1.18

1.06 – 1.31

involved)

revascularization)

involved)
Prospective

1234

SIS>5

2012

(cardiac death and
nonfatal ACS)

Hadamitzky et

Retrospective

17793

al80, 2013

SIS (Number of
segments with any
plaque or stenosis)

Bittencourt et

Retrospective

3242

al106, 2014
Dougoud et al99,

Retrospective

218

2014
Mushtaq et al103,

Prospective

1196

SIS>5

Hard cardiac events

3.09

2.00 – 4.75

Retrospective

2538

Nonobstructive CAD in

All-cause mortality

1.74

1.49 – 2.05

All-cause mortality

4.75

2.1 – 10.75

All-cause mortality

1.17

1.06 – 1.29

1.77

1.3 – 2.42

2015
Ostrom et al114,
2008
Lin et al107,

3 epicardial vessels
Prospective

2583

2011
Chow et al73,

Nonobstructive CAD in
3 epicardial vessels

Prospective

2076

Total plaque score

2010
Hadamitzky et

and non-fatal MI
Prospective

1584

Total plaque score

al24, 2013
Chow et al102,

Death and non-fatal
MI

Retrospective

13966

CAD Severity

All-cause mortality

1.58

1.42 – 1.76

Prospective

521

Plaque volume tertiles

Cardiac events

4.78

2.27 –

2011
Gitsioudis et
al115, 2015

10.04

20

Deseive et al116,

Prospective

1577

High plaque volume

2018

All-cause mortality

6.4

3.2 – 12.8

4.7

3.1 – 7.0

and MI

Nadjiri et al111,

Prospective

1168

SSS

MACE

2016

CAD = coronary artery disease, MACE = major adverse cardiovascular events, MI = myocardial infarction, SIS
= segment involvement score, SSS = segment stenosis score

High risk plaque (HRP) characteristics on CTCA
Coronary CTA allows for the identification of several features of HRP, the quantification of
overall plaque burden and the non-invasive assessment of the degree of luminal narrowing.
Clinical and pathophysiological studies have identified the features of plaque composition and
morphology that are associated with plaque vulnerability and likelihood of future rupture.42, 117,
118

When compared using invasive fractional flow reserve (FFR), HRP features and plaque

volume appear to influence the haemodynamic significance of a coronary stenosis almost to
the same extent as the anatomical degree of luminal narrowing.119, 120 The close relationship
between HRP characteristics and invasive FFR has been demonstrated in several recent
studies,121 with the incorporation of physiological stenosis severity and HRP features providing
better prognostic stratification of patients than with the use of either individual component
alone.122 Many studies investigating HRP characteristics on CTCA have demonstrated an
independent and incremental improvement in prognostication for the low-intermediate
cardiovascular risk cohort.45, 55, 121, 122 However, as discussed in more detail later, these studies
share the collective limitation that they do not adjust for total atherosclerotic plaque burden as
a confounding factor.44, 60
Five major features of high-risk plaque can be identified on CTCA including: positive
remodelling index (PRI), low attenuation plaque (LAP), the napkin-ring sign (NRS), spotty
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calcification and the degree of luminal impingement (MLA) or the percentage area of stenosis.
CTCA plaque types are usually subdivided as either non-calcified (no calcium density),
calcified (the entire plaque appears as calcium density) or partially calcified by SCCT (Society
of Cardiovascular Computed Tomography) criteria, with excellent inter- and intraobserver
agreement.84, 123-125
Minimal luminal area (MLA) and percentage area stenosis
The MLA on CTCA is defined as the narrowest lumen area in a given segment126, while
percentage area stenosis (%AS) at the level of the MLA is defined by [1-(MLA/corresponding
reference lumen area) X 100].98 MLA (Specificity [Sp] 68%; 95% CI, 57%–77%; p=0.001)
and %AS (76%; 95% CI, 65%–84%; p<0.001) both are more specific for detection of
functionally significant lesions when compared to visual analysis alone (42%; 95% confidence
interval [CI], 31%–54%) when using invasive FFR as the reference standard.98
Positive remodelling index (PRI)
The arterial remodelling index (RI) has been defined as the ratio between the outer vessel crosssectional area at the site of maximal luminal narrowing and the mean vessel area of the
proximal and distal reference sites.127, 128 A PRI is often defined as a RI ≥ 1.10.129-131 Arterial
remodelling may be expansive, constrictive, or a combination of the two processes. A positive
remodelling index identifies expansive remodelling, the type most frequently observed during
the development of fibroatheromas.31 In histo-pathological studies, the extent of expansive
remodelling is correlated with lipid core size, plaque inflammation, calcification and medial
atrophy, and is negatively associated with fibrotic regions.67,
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CTCA measurement of

positive remodelling is moderately correlated with that of IVUS and intravascular ultrasound
virtual histology (IVUS-VH),133-135 typically overestimating both PRI and vessel area.135
Nonetheless, numerous studies127, 136, 137 have reported that the RI and plaque area of ACS
lesions (or plaque rupture groups) are larger than those of non-ACS lesions (non-plaque rupture
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groups) as measured on CTCA, indicating the potential utility of PRI in detecting patients of
higher risk. Indeed, in a prospective study of 1059 patients undergoing CTCA for suspected or
known coronary artery disease, Motoyama et al.130 demonstrated that the presence of PRI
and/or LAP on CTCA independently predicted future ACS events (HR 22.8; 95% CI, 6.9-75.2;
p<0.001).
Low attenuation plaque (LAP)
LAP has been defined as a focal, non-calcified plaque with a low-attenuation threshold of <30
HU, with 30-150 HU described as intermediate-attenuation plaque.130, 131, 138, 139 To define the
minimum CT density in a non-calcified plaque, typically 5 regions of interest (areas of 1mm2)
are evaluated for each lesion, with the mean value defined as the plaque density.117, 131, 140 Low
attenuation plaque is correlated directly with the presence of TCFA, although there is
significant overlap between the HU of the lipid-rich and fibrous plaque groups. Increased LAP
volume contributes to positive remodelling, fibrous cap attenuation and impaired vasodilation,
features predisposing to ischaemia and plaque rupture.141 For example, Kashiwagi et al.128
evaluated culprit lesions in 105 patients with ACS and stable angina pectoris (SAP) with CTCA
and OCT. Patients were divided into a TCFA and a non-TCFA group according to OCT
findings, demonstrating that the attenuation value of the culprit plaque in the TCFA group was
significantly lower than the non-TCFA group (35.1± 32.3 HU vs 62.0± 33.6 HU, p<0.001).
Motoyama et al. demonstrated that a proposed cut-off of 30 HU had a sensitivity of 91% and
specificity of 100% for the detection of plaques that matched to low attenuation areas as
detected by IVUS of the corresponding coronary segment.139, 142 In a retrospective study of 60
patients with unstable angina, Madder et al.143 demonstrated that CTCA defined high-risk
plaque (with ulceration or intraplaque contrast penetration) contained more LAP when
compared to non-disrupted lesions (99 ± 161mm3 vs 19 ± 18mm3, p<0.0001). Although
utilising a novel comparator that is yet to be validated, this study emphasises the important

23

association of low-density plaque with unstable coronary lesions. As with PRI, LAP on CTCA
is present more often in patients with ACS compared to those with SAP.139, 144
Napkin-ring sign (NRS)
The NRS was originally described by Tanaka et al.136 and is typically defined by the following
criteria:128, 145
(1) The presence of a ring of higher attenuation around a specific coronary artery plaque, and
(2) The attenuation of the ring being higher than those of the adjacent plaque and no greater
than 130 HU (to differentiate from calcium depositions).
There are several theories regarding the pathogenesis of the napkin-ring sign. These
include intraplaque vasa vasorum contrast enhancement, thrombus with peripheral contrast
enhancement, intraplaque haemorrhage or plaque micro-calcifications. All of these proposed
mechanisms are strongly associated with high-risk plaque. Furthermore, several studies have
demonstrated that vasa vasorum density correlates with plaque progression. This suggests that
the NRS may be a potential surrogate marker of future plaque vulnerability.146, 147
Several small prospective studies and case reports utilising a variety of comparators,
including IVUS, OCT and histopathological analysis, have suggested that the NRS represents
a CTCA specific feature of a TCFA.128, 136, 148 For example, in a prospective study of 108
patients with coronary artery disease, Kashiwagi et al. demonstrated that the NRS in the OCTdefined TCFA group was eleven times more frequent than in the non-TCFA group (44% vs.
4%, p<0.0001). However, while this sign has been shown to be highly specific for the
prediction of TCFA,149, 150 this is at the cost of lower sensitivity, with one study demonstrating
a specificity of 96% and a sensitivity of 44%.128 Otsuka et al.131 prospectively examined 894
patients who were being investigated for stable chest pain over a mean follow-up of 2.3 years,
demonstrating that the napkin-ring sign was of significant prognostic importance for future
ACS events, independent of other high-risk CTCA plaque features, including PR and LAP

24

(HR: 5.55, 95% CI 2.10–14.70, p<0.001). Similarly, in a prospective cohort study of 1469
patients who presented with either atypical chest pain, stable angina or were asymptomatic
with a high risk of CHD, Feuchtner et al.151 demonstrated that the CTCA findings that were
the strongest predictors of MACE were LAP <60 HU and the NRS.
Spotty calcification
Spotty calcification on CTCA is defined as a small, highly attenuated (>130 HU) plaque
component that is surrounded by non-calcified plaque tissue,42 typically described as <3mm in
size on curved multiplanar reformation (MPR) images.129, 139, 152 Spotty calcifications on CTCA
have been further characterised as small (<1mm), intermediate (1-3mm) or large (>3mm), with
small spotty calcifications showing the strongest association with vulnerable plaque features
on IVUS-VH.153 Motoyama et al.139 reported that spotty calcification was significantly more
frequent in the culprit lesions of patients with ACS when compared to the target lesions of
those with SAP (63% vs 21%, p<0.0005). In one study of 57 patients, Ozaki et al.129
demonstrated that spotty calcification was more frequent in patients with ACS with ruptured
fibrous cap lesions compared to those with intact fibrous cap lesions (20% vs 80%, p=0.001)
and when compared to those with SAP (80% vs 23%, p=0.001). Similar findings are reported
by several other studies.117, 144, 154

Current methods of risk stratification following an ACS
The risk stratification of the ACS patient may be performed in two distinct stages. The first
stage involves the estimation of the risk of a patient with suspected ACS, a situation where the
diagnosis is yet to be confirmed. This is accomplished through the evaluation of history,
physical examination, clinical risk scores (i.e. HEART155 and TIMI156 scores) and relevant
biomarkers (i.e. high-sensitivity cardiac troponin [hs-cTn]). Further risk stratification of highrisk patients with suspected ACS is usually through evaluation by ICA.
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The second stage involves evaluating the risk of recurrent ACS event in a patient with
confirmed ACS. Current risk stratification models for the post-ACS patient group typically
utilise the Gensini157, SYNTAX (Synergy between Percutaneous Coronary Intervention with
TAXUS and Cardiac Surgery)158 or GRACE (Global Registry of Acute Coronary Events)159
scores, although these are infrequently used for this purpose in clinical practice.
Biomarkers
According to the Fourth Universal Definition of Myocardial Infarction,28 an acute myocardial
infarction is defined by elevated cardiac troponin values (cTn) with at least one value above
the 99th percentile URL, with a rise and/or fall of cTn values, in the presence of particular
clinical, ECG or imaging findings. The presence of elevated cTn in patients with ACS
differentiates myocardial infarction from unstable angina. Beyond presence or absence, as
included in the GRACE score, higher levels of cardiac troponin have been correlated with a
larger infarct size and as might be anticipated, also a greater mortality risk.160,
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The

measurement of several different biomarkers (hs-cTn, CRP, BNP, NT-proBNP, HbA1c,
Lipoprotein(a) [Lp(a)] etc.) has been shown to provide additional prognostic information
beyond traditional risk predictors in the post-ACS population.162-166 For example, in a study167
of 6,809 patients, increasing quartiles of NT-proBNP measured soon after admission were
associated with increasing mortality rates of 1.8%, 3.9%, 7.7%, and 19.2% at 1-year of followup. Recently cysteine-rich angiogenic inducer 61 (Cyr61), a novel biomarker of plaque stability
during acute coronary occlusion, independently improved risk stratification beyond the
GRACE score alone at 1 year (c= 0.77 to c=0.80, p< 0.001).168 Likewise, a recent study by
Wildera et al.169 demonstrated incremental predictive value with the use of hs-cTn (c=0.763;
95% CI: 0.710 to 0.816) and BNP (c=0.773; 95% CI: 0.717 to 0.82) when compared to the
GRACE score alone (c=0.749; 95% CI: 0.696–0.801, all p<0.001). While the role of cTn in
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the post-ACS cohort is clear, the prognostic value of these other biomarkers remains to be
determined.
Clinical risk scores
While there are several clinical risk scores used for the prediction of short and long-term risk
in post-ACS patients (i.e. the TIMI score), the most widely used and recommended by
guidelines is the GRACE score, which will be the main focus of our discussion. The GRACE
score is calculated based on patient age, Killip Class, systolic blood pressure, the presence of
ST segment deviation, cardiac arrest during presentation, serum creatinine concentration,
elevated serum cardiac markers (e.g. troponin) and heart rate. Multiple studies have validated
this scoring system in the post-ACS population.16, 170 A meta-analysis171 of 216,552 patients
from 40 derivation studies and 31,625 patients from 42 validation studies demonstrated a cstatistic of 0.82 (95% CI: 0.80-0.89) and 0.84 (95% CI: 0.82-0.87) at short and long term
follow-up of post-ACS patients, respectively. The GRACE score 2.0 is an updated and refined
score based on the outcomes of the GRACE registry, comprising 32,037 patients across 14
countries. This score has been validated in a French registry172 of 3059 patients, providing inhospital, 6-month, 1-year and 3-year mortality. This study demonstrated a c-statistic of 0.82
for death at 1 and 3 years, with slightly lower discrimination for death or myocardial infarction
(c=0.78). While being cheap, relatively easy to use and providing moderate to good prediction
of prognosis post-ACS, the GRACE and GRACE score 2.0 do not account for the
individualised burden of anatomical coronary disease, including high-risk plaque features and
several other factors.
Angiographic complexity
The majority of ACS patients who are not low risk may undergo catheter-based coronary
angiography and revascularisation of culprit lesions to reduce the risk of future cardiovascular
events. Diagnostic angiography enables assessment of the angiographic complexity of
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coronary disease, an important predictor of future and recurrent events.173-175 Various
approaches have been used, most commonly the Gensini score,157 while the SYNTAX score
has been recently validated with outcome data and is currently recommended to facilitate risk
assessment in international guidelines.176, 177 Neither were specifically developed for ACS
populations.
The most widely utilised score178 to quantify angiographic coronary artery disease is
the Gensini score. Developed by Gensini in 1983,157 the Gensini score evaluates the severity
of individual coronary lesions while considering the cumulative effects of multiple obstructions
and the functional significance of their location within the coronary tree. The Gensini score
correlates well with average percent plaque burden (%) (r=0.76, p<0.0001) and moderately
with average plaque area (mm2) (r=0.58, p<0.0001) as measured by intravascular ultrasound
(IVUS).178
The SYNTAX score is a lesion-based scoring system, calculated based on the interpretation of
the images obtained during ICA, allowing for the objective quantification of the complexity of
coronary artery disease. The SYNTAX score has been shown to be a strong predictor of
outcome in single vessel, multi-vessel and left main CAD treated by PCI174, 179, 180 and in left
main CAD treated with CABG,181 but not in the minority of ACS patients who undergo
CABG.182 One study183 demonstrated a c-statistic for the SYNTAX score of 0.62 (95% CI:
0.52-0.73, p=0.03) and 0.59 (95% CI: 0.53-0.65, p=0.002) for the prediction of 5-year mortality
and 5-year major adverse cardiovascular events (MACE), respectively. Typically, the
SYNTAX score is used to guide the optimal selection of revascularisation therapy (either
CABG or PCI) in patients with CAD.184, 185 The recently developed SYNTAX II score,186
augmented by clinical variables (including age, serum creatinine and left ventricular ejection
fraction [LVEF]) has also been externally validated,187 providing another system to guide the
decision between revascularisation with PCI versus CABG. While both Gensini and SYNTAX
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scores appropriately give higher weighting to more proximal plaque, they are indirect measures
of plaque burden, with neither directly measuring plaque burden, plaque composition, nor
evaluating high-risk plaque features identifiable only within the vessel wall
Impact of CTCA on clinical decision-making and outcomes
There are currently no trials that have evaluated the utility of CTCA in altering clinical decision
making and improving outcomes for the post-ACS patient group. However, there are several
trials that have examined the effect of CTCA on management and subsequent clinical outcomes
in the low to intermediate risk population. The landmark SCOT-HEART trial188 randomised
4,146 low to intermediate cardiovascular risk outpatients with suspected angina from 12
cardiology chest pain clinics across Scotland, to receive either standard care or standard care
and assessment with CTCA. The primary endpoint of the study was the proportion of patients
diagnosed with angina pectoris secondary to coronary heart disease at 6 weeks. At 6 weeks,
CTCA reclassified the diagnosis of CAD in 27% of patients and the diagnosis of angina
secondary to CAD in 23%, changing the future utilisation of investigations (15% vs 1%,
p<0.0001) and treatment (23% vs 5%, p<0.0001) significantly. CTCA was associated with a
20% increase in the utilisation of ICA at 6 weeks, although the proportion of revascularisation
was similar (11.2 vs 9.7%; p=0.0611). After 1.7 years of follow-up, the utilisation of CTCA
was associated with a substantial reduction in fatal and nonfatal myocardial infarction
(HR=0.62, 95% CI 0.38-1.01; p=0.0527), although this was not statistically significant and
event rates were low in both arms. Post-hoc analysis189 of the SCOT-HEART data from the
median time for preventative therapy initiation (50 days) demonstrated that the use of CTCA
led to more appropriate utilisation of ICA and preventative medical therapy, manifesting as a
halving of the rate of fatal and non-myocardial infarction compared to management with
standard care alone (HR: 0.50, 95% CI 0.28-0.88, p=0.020). This post-hoc analysis would later
be confirmed in the 5-year follow-up study,190 where the CTCA group had a significant
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reduction in death from coronary heart disease or nonfatal myocardial infarction compared to
the standard of care group (2.3% vs. 3.9%; HR=0.59, 95% CI 0.41-0.84; p=0.004).
Furthermore, overall rates of coronary revascularisation (HR 1.07, 95% CI 0.91-1.27) and ICA
(HR 1.00, 95% CI 0.88-1.13) were similar between groups at 5 years.
The PROMISE trial191 randomised 10,003 participants from 192 centres across the
USA and Canada to diagnostic testing with either CTCA or functional stress testing, with a
primary endpoint of death, nonfatal MI, hospitalization for unstable angina and major CV
procedural complications (anaphylaxis, stroke, major bleeding, and renal failure). In contrast
to the SCOT-HEART trial, at 25 months of follow-up, there was no statistically significant
difference in the rate of the primary endpoint between groups, with 3.3% (164/4996) of patients
in the CTA group and 3.0% (151/5007) of patients in the functional-testing group experiencing
an event (adjusted HR: 1.04; 95% CI 0.83-1.29; p=0.75), although some authors have criticised
this trial for being underpowered.192, 193 Furthermore, there was a significant increase in the
rate of coronary revascularisation in patients randomised to receive CTCA compared to the
functional stress testing group (6.2% vs 3.2%; p>0.001). Several other smaller trials have
recently examined the effect of CTCA on clinical outcomes, demonstrating a reduction in the
number of hospital admissions and investigations,194 with equivocal results pertaining to
cardiovascular event rates and mortality.195, 196 Overall, there is certainly promise that the
utilisation of CTCA may directly improve clinical outcomes, increase diagnostic accuracy and
reduce cost in the low to intermediate risk cohort. Indeed, utilizing CTCA in the post-ACS
cohort could identify patients who are most likely to benefit from therapy with proprotein
convertase subtilisin/kexin type 9 (PSCK9) inhibitors or other novel therapies, resulting in a
reduction in MACE (major adverse cardiovascular events) and/or mortality.197 However, it
remains less likely that such a benefit in clinical outcomes would translate to the post-ACS
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cohort given that most contemporary interventions and medical therapies are applied broadly
to all within this patient group.

CTCA for the risk stratification and diagnosis of patients presenting with suspected ACS
Several randomised control trials have evaluated the role of CTCA in the risk stratification of
patients with chest pain presenting to the emergency department. For example, the randomised
control ROMICAT-II (Rule Out Myocardial Infarction/Ischemia Using Computer Assisted
Tomography)25 trial enrolled 1,000 patients without ischaemic changes on ECG or elevated
initial troponin into either assessment with early CTCA or standard evaluation. There was an
7.5% rate of observed myocardial infarction in this group, representing a population of
intermediate cardiovascular risk. Patients randomised to the early CTCA group had a
significant reduction in their mean length of hospital stay (23.2 vs 30.8 hours; p<0.001) with
significantly more patients discharged directly from the hospital department (47% vs 12%;
p<0.001). However, there was no evidence of a reduction in the mean cumulative cost of care
between groups ($4,289 vs $4,060; p=0.65) and there was increased downstream testing and
radiation exposure in the CTCA group. Importantly, there were no undetected acute coronary
syndromes and no difference in MACE (major adverse cardiac events) between groups at 1
month.
Two other trials examining CTCA in the emergency department, The CT-STAT
(Coronary Computed Tomographic Angiography for Systematic Triage of Acute Chest Pain
Patients to Treatment)198 trial and ACRIN-PA (CT Angiography for Safe Discharge of Patients
with Possible Acute Coronary Syndromes)26 trial, also demonstrated a significant reduction in
the time to diagnosis and decreased length of stay. A meta-analysis199 compared the utilisation
of CTCA versus usual care in the emergency department, demonstrating decreased length of
stay and cost savings with the use of CTCA, although with a significant increase in the rate of
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ICA (OR: 1.36, 95% CI 1.03-1.80; p=0.030) and revascularisation (OR: 1.81, 95% CI 1.202.72, p=0.004). However, the BEACON (Better Evaluation of Acute Chest Pain with
Computed Tomography Angiography)200 trial suggested that in the era of hs-CTN, CTCA does
not shorten hospital stay, allow for increased direct discharge from ED or identify patients with
significant CAD requiring revascularisation. Nevertheless, the use of CTCA was associated
with less outpatient testing (4% vs. 10%, p < 0.01) and reduced costs (€337 vs. €511, p < 0.01)
compared with contemporary standard of care.
In a retrospective analysis of 472 patients presenting with acute chest pain from the
CTCA arm of the ROMICAT-II trial, Puchner et al.55 demonstrated that high risk plaque
features on CTCA were more frequent in those who were ultimately diagnosed with ACS and
remained a significant predictor of ACS after adjustment for ≥50% arterial stenosis and clinical
risk evaluation (OR: 8.9, 95% CU 1.8-43.3; p<0.006). The presence of arterial stenosis ≥50%
on CTCA was also a significant predictor of ACS (RR: 34.4, 95% CI 16.7-70.7, p<0.001). In
another observational, retrospective analysis201 of 160 patients from the ROMICAT-II trial
who had both hs-cTN measured and CTCA performed, the CTCA assessment of high-risk
plaque features, coronary artery stenosis ≥50% and measurement of hs-cTN significantly
improved discriminatory ability for ACS when compared to conventional troponin and
traditional CTCA assessment (AUC: 0.74 to 0.84; p <0.001). The use of CTCA reclassified
71.9% of those with intermediate hs-cTN, decreasing the fraction of patients remaining at
intermediate risk of ACS from 43.8% to 24.4%. The assessment of HRP features on CTCA
when compared to traditional CTCA assessment, improved the specificity for the diagnosis of
ACS from 48.2% to 68.1%. The exclusion of HRP and arterial stenosis in this setting has been
hypothesised to decrease downstream testing such as ICA. Further studies are needed to
confirm if the use of CTCA and hs-cTN in the emergency department could translate into
reduced utilisation of ICA for patients with suspected ACS.
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Model for CTCA and the risk stratification of the post-ACS population
The utilisation of CTCA may have an important role in identifying patients post-ACS who are
at increased risk of a recurrent event. The quantification of plaque burden, plaque composition
and the identification of HRP characteristics, may provide incremental benefit when combined
with current models of risk estimation (i.e. GRACE and SYNTAX scores) in this high-risk
cohort, allowing for improved risk stratification and the identification of individuals most
likely to benefit from more expensive or novel therapeutics (see Figure 4). While there are only
several studies examining the long-term prognostic utility of CTCA assessment of plaque
burden in the post-ACS population,105, 202 additional inference can be made from extensive
research in the low to intermediate risk population and in patients with suspected ACS
presenting to the emergency department.

CTCA as a gatekeeper for invasive angiography for patients with troponin-positive ACS
For the assessment of patients with confirmed troponin-positive ACS, the integration of CTCA
into contemporary clinical practice remains problematic. An additional CTCA scan following
ICA is not feasible due to additional radiation and contrast exposure. It is unlikely that the
identification of HRP and plaque quantification for risk stratification could justify such an
approach. However, the adoption of a role as a gatekeeper for ICA in lower risk ACS patients
could potentially represent a viable alternative for the integration of CTCA into contemporary
workflow.
ICA, in combination with OCT and IVUS, remains the gold-standard for the anatomical
assessment of coronary arterial stenosis, with excellent spatial and temporal resolution.
However, more frequently ICA is used in combination with FFR, with OCT and IVUS typically
utilised in academic centres. Perhaps even more significantly, ICA facilitates the performance
of PCI immediately following imaging. Yet, diagnostic ICA is invasive, resource intensive,
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Figure 1.4: Potential model for the role of CTCA in defining risk in the post-ACS cohort
This figure demonstrates a theoretical pathway for the integration of CTCA for risk stratification following ACS
into clinical practice.

ACS = acute coronary syndrome, CTCA = computed tomography coronary angiography, DAPT = dualantiplatelet therapy, PCSK9 = proprotein convertase subtilisin/kexin type 9 inhibitors, NOAC = non-vitamin K
antagonist oral anticoagulant
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and associated with rare, although serious complications, including vascular complications
(0.5%), contrast reactions (0.23%), cerebrovascular accident (0.07%), acute myocardial
infarction (0.06%) and death (0.1%).203 Furthermore, diagnostic ICA has been associated with
a higher estimated mean effective radiation dose when directly compared to CTCA (8.5+/4.4mSv vs 2.1+/- 0.7mSv, p<0.001).204
Current guidelines mandate emergent ICA for PCI-mediated reperfusion in patients
with STEMI or occlusive myocardial infarction and it is unlikely there could be any role for
CTCA in this setting as it would lead to unacceptable delays in revascularisation.29 However,
CTCA could potentially act as a gatekeeper in ACS patients with NSTEMI/UA, or more
precisely, those with non-occlusive myocardial infarction who are unlikely to require emergent
reperfusion, who account for approximately 75%205-207 of the ACS population. Particularly in
settings where patients with lower risk NSTEMI/UA do not undergo emergent angiography
within 24 hours, a transition to utilising CTCA as an ICA sparing measure may be feasible,
although some institutions have a policy of an early invasive approach even in this patient
group. Based on the estimated radiation doses described above, it can be calculated that if one
out of four patients undergoing CTCA did not require a subsequent ICA, overall mean
estimated radiation dosage would be lower (33.9mSv vs 34mSv). The development of FFR
CT and stress CT perfusion techniques may further define which of these lower risk ACS
patients may benefit from ICA and reperfusion.
Furthermore, CTCA may have a role in the diagnosis of the MINOCA patient group,
who account for approximately 6% of patients who present with myocardial infarction.208 The
aetiology of MINOCA includes, but is not limited to, coronary vasospasm, myocarditis,
pulmonary embolism, cardiomyopathy (takotsubo, dilated, hypertrophic), tachyarrhythmiamediated, renal impairment, stroke, septic shock, spontaneous coronary artery dissection,
Factor V Leiden, Protein C and S deficiency, sympathomimetic-induced spasm (i.e. cocaine)
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or microvascular dysfunction/embolization.209 One suggested approach in determining the
aetiology of MINOCA is to first rule out non-ischaemic causes of troponin elevation with
clinical evaluation and cardiac magnetic resonance imaging. Secondly, investigation into other
causes with thrombophilia screening, coronary microvasculature assessment and coronary
vasospasm testing should be considered.210 The utilisation of CTCA in this setting may not
only reduce the use of unnecessary ICA, but also identify radiographic features of pulmonary
embolism, aortic dissection and cardiomyopathy. In one study, 36.8% of MINOCA patients
had angiographically normal coronary arteries, with 65.2% demonstrating stenosis <50%.211
CTCA may have a role in the detection of atherosclerotic disease in the vessel wall of patients
with angiographically normal coronary arteries, identifying those who would benefit from
medical therapy. Furthermore, two-thirds of MINOCA patients present with NSTEMI,208
representing a group that may be more safely evaluated by CTCA, as emergent ICA is not
mandated. Nonetheless, for the evaluation of patients with MINOCA, cardiac magnetic
resonance provides a higher diagnostic yield and remains the non-invasive imaging
investigation of choice212.

Limitations of CTCA for the evaluation of patients following ACS
There are several factors which may limit the use of CTCA in the post-ACS setting. Cost and
radiation exposure remain the primary concern of healthcare legislators. However, radiation
doses of approximately 3mSv188,
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are now frequently achieved with the use of modern

scanners, with a dose reduction of 70-80% accomplished over the previous 10 years.193
Furthermore, high contrast volumes are associated with an increased risk of contrast-induced
nephropathy.214 Cost also remains a concern, as randomised trials in the low to intermediate
cardiovascular risk groups have failed to clearly demonstrate reduced cost with the use of
CTCA.25, 199

36

Clinically, CTCA does not provide substantial information regarding the functional
significance of CAD. There is also a concern that the use of CTCA in the post-ACS group may
offer less utility than in a lower risk setting. As most ACS patients currently undergo ICA prior
to CTCA, CTCA must offer a distinct incremental diagnostic advantage if it is to represent a
viable imaging modality in this setting. It is likely that any incremental diagnostic improvement
will relate to the identification of HRP characteristics, plaque composition and quantification
of plaque burden, however this has not been confirmed.
In addition, molecular imaging modalities, such as 18F-sodium fluoride positron
emission tomography (18F-NaF PET), bis-5HT-DTPA-Gd molecular magnetic resonance
imaging and near-infrared fluorescence OCT or IVUS, may allow for the early detection of
vulnerable high-risk plaque and more active atherosclerotic disease in patients following ACS,
although further research is required before defining any role in clinical practice215-217.
Another limitation is that most patients in the high-risk post-ACS group are already
prescribed adequate secondary prevention therapy. This means that unlike the low to
intermediate risk group, clinical outcomes may not be meaningfully improved with changes in
medication prescription. Therefore, improving risk stratification in this patient group may not
alter clinical management significantly.
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CHAPTER TWO – ASSOCIATION BETWEEN COMPUTED TOMOGRAPHY
CORONARY ANGIOGRAPHY (CTCA)-DERIVED RESIDUAL PLAQUE BURDEN
COMPOSITION AND CLINICAL AND ANGIOGRAPHIC RISK SCORES IN
PATIENTS FOLLOWING AN ACUTE CORONARY SYNDROME

Numerous studies have demonstrated the value of CTCA for the risk stratification of low and
intermediate cardiovascular risk patients, where in addition to providing an evaluation of
luminal patency, it can identify, quantify and characterise plaque within the vessel wall.17, 58
However, despite extensive research supporting clinical use in low and intermediate
cardiovascular risk patients,190 there is limited research investigating the value of CTCA for
the risk stratification of the high-risk post-ACS cohort. Likewise, the utility of quantifying nonculprit lesion plaque on CTCA has not been thoroughly investigated. Indeed, although
providing an inferior evaluation of luminal patency when compared to ICA, CTCA could
theoretically improve risk-stratification following an ACS through the characterisation and
quantification of plaque within the vessel wall by visualising anatomy not seen on ICA.
The development of software for the semi-automatic and automatic quantification of
plaque burden on CTCA has improved feasibility, reproducibility and accuracy,218 with several
studies demonstrating the incremental advantage of automated plaque quantification beyond
conventional CTCA analysis in patients with stable coronary artery disease.111-113 Currently,
the use of risk scores are recommended to identify the risk of death and recurrent MACE
following an ACS, including the SYNTAX158 score, derived from ICA, and the GRACE159
score, derived from a composite of clinical parameters.171, 180 However, there are a limited data
on the association between CTCA quantified plaque and these risk scores used for
prognostication.
Therefore, the present study aimed to explore the association between CTCA-derived
residual plaque burden components and risk scores that have been validated as predictors of
mortality and MACE (GRACE and SYNTAX scores) in patients following an ACS.
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A. METHODS
Study design and population
All patients enrolled in the MOTIVATOR (Multi-modality imaging and biomarkers to improve
risk stratification for secondary prevention after acute coronary syndrome) study219 who
underwent CTCA within 40 days of ICA were selected. Patients aged 18 years or older were
eligible if they were admitted to hospital with a NSTEMI, STEMI or unstable angina and
proceeded to inpatient ICA, and if all three major epicardial coronary arteries (left anterior
descending, left circumflex, right coronary artery) were suitable for analysis by OCT.
Exclusion criteria included: A calculated eGFR <40 ml/min or <60 ml/min with diabetes
mellitus, unlikely to survive for at least three years due to comorbidity, coronary anatomy
unsuitable for OCT, pregnancy, or previous coronary artery bypass grafting. This study was
approved by the Royal Perth Hospital Human Research Ethics Committee (approval number:
REG 15-033). All participants provided written informed consent.
Demographic variables, comorbidities and medication were recorded by questionnaire.
Height, weight, pulse rate, systolic and diastolic blood pressure were also documented.
Additionally, the GRACE score,159 derived from a combination of patient age, Killip class,
systolic blood pressure, the presence of ST segment deviation, cardiac arrest during
presentation, serum creatinine concentration, serum cardiac markers and heart rate, was
calculated for all participants at the baseline visit.

Invasive coronary angiography
ICA was performed as part of clinical care during the index hospitalization via the transradial
or transfemoral route, according to local best practice. The angiographic views obtained, visual
interpretation and decisions regarding the need for revascularization and revascularization
strategy, were at the discretion of the interventional cardiologists responsible for the clinical
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care of each patient on the day of their procedure. Coronary angiography images were
independently reviewed by a cardiologist, who calculated the SYNTAX score for each patient,
while blinded to the CTCA analysis. The SYNTAX score was calculated using the online
calculator http://www.syntaxscore.com.

CTCA data acquisition
All CTCA images were acquired by a 64-multidetector row scanner (Phillips iCT with IMR,
or Siemens Definition AS+) within 40 days of ICA. Isotropic voxel size was 0.5 x 0.5 x 0.5
mm or smaller, gantry rotation time 330 ms or less, with a temporal resolution of ≤ 165 ms and
collimation of 0.625 mm. The target heart rate for CTCA was < 65 beats per minute. Heart rate
was controlled according to local protocol, with oral metoprolol 50 mg, or in the case of betablocker intolerance, ivabradine 7.5 mg. Additional medication was given if required to reach
the target heart rate. Radiation dose was minimised through the utilization of prospective ECGtriggered tube current modulation, limiting the maximum dose to the diastolic phase of the
cardiac cycle resulting in an average radiation dose received of 3 mSv per scan. Image slices
were reconstructed at 0.5 mm slice thickness at an increment of 0.5 mm. The contrast volume
was adjusted according to body size and the mean contrast volume was 122 (±31) ml.

Quantification of residual plaque burden on CTCA
Semi-automatic quantification of coronary plaque burden was performed utilizing previously
validated, dedicated CTCA software (QAngio CT RE, Version 3.1, Medis, Leiden, the
Netherlands) by a single reader, S.B, who was blinded to clinical data and ICA results.220, 221
Initially, an automatic tree extraction algorithm was used to derive straightened and curved
MPR volumes for each coronary vessel. Each coronary artery was then divided into segments
according to the Society of Cardiovascular Computed Tomography guidelines.222 Luminal and
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vessel wall contours were then analysed in 0.5 mm transverse cross-sections perpendicular to
derived centrelines (Figure 1).223 Classification into low attenuation, fibro-fatty, fibrotic and
dense calcified plaque was performed automatically using dynamic adaptive HU thresholds
adjusted according to an algorithm based on luminal contrast densities, a method previously
validated by IVUS.221, 224 Plaque quantification was performed in all coronary vessels until
luminal diameter was less than 2 mm. Plaque burden was calculated by the formula: (plaque
area / vessel area) X 100. To define residual plaque burden, stented sections of each segment
were excluded from the final analysis. Five parameters of residual plaque burden were derived:
1. Total residual plaque burden (%): defined as the total plaque burden of all analyzed
coronary segments excluding stented sections.
2. Residual low attenuation plaque burden (%): defined as the total low attenuation plaque
burden of all analyzed coronary segments excluding stented sections.
3. Residual dense calcified plaque burden (%): defined as the total dense calcified plaque
burden of all analyzed coronary segments excluding stented sections.
4. Residual fibro-fatty plaque burden (%): defined as the total fibro-fatty plaque burden
of all analyzed coronary segments excluding stented sections.
5. Residual fibrotic plaque burden (%): defined as the total fibrotic plaque burden of all
analyzed coronary segments excluding stented sections.
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Figure 2.1: Examples of the calculation of residual plaque burden on CTCA
Panel A demonstrates a curved MPR image of the RCA. The orange contour represents the outer vessel wall,
while the yellow contour represents the luminal wall. Panel B demonstrates a transverse slice of the RCA seen in
panel A. The area in between the orange and yellow contours is calculated as plaque area, while vessel area is
calculated as the area within the orange contour. Residual plaque burden is then calculated as: (plaque area / vessel
area) X 100 for each transverse slice and summated for each segment, excluding stented sections. Panel C
demonstrates a curved MPR image of the LM and LAD for a different patient, with a transversal slice seen in
panel D. There are no stented sections in this example, so residual plaque burden is equal to plaque burden.

CTCA = Computed tomography coronary angiography, dLAD= Distal left anterior descending coronary artery,
dRCA = Distal right coronary artery, LAD = Left anterior descending coronary artery, LM = Left main coronary
artery, mLAD = Mid-left anterior descending coronary artery, MPR = Multiplanar reformatted, mRCA = Midright coronary artery, pLAD = Proximal left anterior descending coronary artery pRCA = Proximal right coronary
artery, RCA = Right coronary artery
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Statistical analysis
Categorical variables are expressed as numbers and percentages. The Kolmogorov–Smirnov
test and visual assessment of histograms were used to examine for adherence to a normal
distribution. Normally distributed continuous variables are presented as mean ± standard
deviation whilst variables that are non-normally distributed are presented as median and
interquartile range. Categorical variables were compared using the χ2 test. Continuous variables
were compared using the Student t-test if normally distributed, while the Mann-Whitney Utest was utilized for non-normally distributed variables. Pearson correlation was used to
investigate the relationship between normally distributed variables, whereas Spearman
correlation was used if parameters were not normally distributed. Ten random individuals were
selected for evaluation of intraobserver agreement using scatter plots, intraclass correlation
coefficients (ICCs) and Bland Altmann analysis. Intraobserver measurements were performed
offline after a two-week interval. All tests were two-sided and p-values <0.05 were considered
statistically significant. All statistical analyses were performed using SPSS version 25.0 (SPSS,
Chicago, IL).

B. RESULTS
Clinical Characteristics
A total of 75 patients were recruited from the department of cardiology at Royal Perth Hospital
according to the study protocol. Of these, 62 patients underwent CTCA within 40 days of
enrolment (Figure 2). One patient was excluded from CTCA analysis due to inadequate image
quality (feasibility, 98%). The mean age of participants was 61.3 (±9.2) years, 85% were of
male sex, 7% had a previous history of myocardial infarction, 54% of patients had
hypertension, 44% dyslipidemia, 18% diabetes mellitus, 8% chronic kidney disease and 31%
were current smokers. The mean GRACE score was 123 (±25), the median SYNTAX score
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was 11 (interquartile range, 5.5 to 19), while the median number of stents per patient was 2,
with 52 patients (85%) receiving at least one stent. Additional clinical characteristics are
summarized in Table 1.

Figure 2.2: Study Flow Chart

CTCA = Computed tomography coronary angiography, ICA = Invasive coronary angiography, MOTIVATOR
study = Multi-modality imaging and biomarkers to improve risk stratification for secondary prevention after acute
coronary syndrome study
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Table 2.1: Patient characteristics
Variable

Total population
(n=61)

GRACE Score
<123 (n=30)

GRACE Score
≥123 (n=31)

p-value

Age, years

61.3 (±9.2)

57.5 (±8.0)

67.0 (±8.9)

p=0.001

52 (85%)

28 (93%)

24 (77%)

p=0.080

23 (38%)

15 (50%)

8 (26%)

p=0.051

Male sex
2

Obesity (BMI>30kg/m )
CKD
(eGFR<60ml/min/1.73m2)
Diabetes mellitus

5 (8%)

1 (3%)

4 (7%)

p=0.173

11 (18%)

5 (17%)

6 (19%)

p=0.79

Hypertension

33 (54%)

18 (60%)

15 (48%)

p=0.36

4 (7%)

2 (7%)

2 (7%)

p=0.97

Smoking

19 (31%)

15 (50%)

4 (13%)

p=0.002

Dyslipidemia

27 (44%)

13 (43%)

14 (45%)

p=0.89

Number of stents

2 (1 to 2)

1 (1 to 2)

2 (1 to 2)

p=0.50

SYNTAX score

11 (5.5 to 19)

7.5 (5.75 to 16.25)

13.0 (5 to 22)

p=0.13

1180 (162 to 10105)

1330 (163 to 6355)

p=0.59

146.0 (135.0 to
154.0)
5.0 (±1.2)

147.5 (137.8 to
153.0)
5.2 (±1.3)

1100 (148 to
18500)
140.3 (133.0 to
154.0)
4.7 (±1.0)

3.1 (±1.0)
10.2 (±2.6)

3.2 (±1.1)
10.1 (±2.4)

2.9 (±0.8)
10.2 (±2.8)

p=0.32
p=0.84

Previous history of MI

Blood test results
High sensitivity cardiac
troponin, ng/L
Hb, g/L
Total Cholesterol,
mmol/L
LDL, mmol/L
WCC, 109/L

p=0.33
p=0.11

Data are presented as mean± SD if normally distributed or median (25th-75th percentile) if not normally
distributed
BMI = Body mass index, CKD = Chronic kidney disease, GRACE score = Global Registry of Acute Coronary
Events score, Hb = Haemoglobin, LDL = Low-density lipoprotein cholesterol, MI = Myocardial infarction,
SYNTAX score = Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery score,
WCC = White cell count

CTCA
Quantitative CTCA analysis demonstrated that mean total residual plaque burden was 39.0
(±5.4) %, composed of 60% fibrotic plaque, 25% fibro-fatty plaque, 9% low-attenuation plaque
and 6% dense-calcified plaque. Mean non-calcified residual plaque burden was 36.2 (±4.3) %,
while median residual dense calcified plaque burden was 1.1 %. Of the non-calcified residual
plaque, mean low attenuation plaque burden was 3.5 (±1.0) %, mean fibro-fatty plaque burden
was 23.0 (±3.5) % and mean fibrotic plaque burden was 9.7 (±1.8) %. When the population
was dichotomized according to median GRACE score, the upper quantile had a higher total
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residual plaque burden, a higher residual fibrotic plaque burden and a higher residual dense
calcified plaque burden. CTCA characteristics are summarized in Table 2.2 and Table 2.3.
Table 2.2: CTCA characteristics according to GRACE score
Variable:

Total population
(n=61)
Quantitative CTCA Parameters
Total residual plaque
burden, %
Residual low attenuation
plaque burden, %
Residual dense calcified
plaque burden, %
Residual fibro-fatty plaque
burden, %
Residual fibrotic plaque
burden, %
Contrast volume, ml

GRACE Score <123
(n=30)

GRACE Score ≥123
(n=31)

p-value

39.0 (±5.4)

36.5 (±4.6)

41.3 (±5.1)

p<0.001

3.5 (±1.0)

3.2 (±0.9)

3.7 (±1.1)

p=0.051

1.1 (0.5 to 3.3)

0.8 (0.4 to 1.8)

2.1 (0.8 to 4.0)

p=0.008

9.7 (±1.8)

9.4 (±1.8)

10.1 (±1.8)

p=0.15

23.0 (±3.5)

22.0 (±3.1)

23.9 (±3.7)

p=0.042

122 (±31)

123 (±29)

122 (±34)

p=0.84

Data are presented as mean± SD if normally distributed or median (25th-75th percentile) if not normally
distributed
CTCA = Computed tomography coronary angiography, GRACE score = Global Registry of Acute Coronary
Events score
Table 2.3: CTCA characteristics according to SYNTAX score
Variable:

Total population
(n=61)
Quantitative CTCA Parameters
Total residual plaque
burden, %
Residual low attenuation
plaque burden, %
Residual dense calcified
plaque burden, %
Residual fibro-fatty plaque
burden, %
Residual fibrotic plaque
burden, %
Contrast volume, ml

SYNTAX Score <11
(n=30)

SYNTAX Score ≥11
(n=31)

p-value

39.0 (±5.4)

37.5 (±4.4)

40.4 (±5.9)

0.039

3.5 (±1.0)

3.2 (±1.2)

3.6 (±0.8)

0.13

1.1 (0.5 to 3.3)

0.8 (0.4 to 2.4)

1.5 (0.6 to 3.9)

0.23

9.7 (±1.8)

9.3 (±2.0)

10.1 (±1.6)

0.09

23.0 (±3.5)

22.6 (±2.7)

23.4 (±4.1)

0.35

122 (±31)

119 (±25)

126 (±36)

0.37

Data are presented as mean± SD if normally distributed or median (25th-75th percentile) if not normally
distributed
CTCA = Computed tomography coronary angiography, GRACE score = Global Registry of Acute Coronary
Events score

46

Relationship between CTCA-derived residual plaque burden, GRACE and SYNTAX
scores
Correlations between parameters of residual plaque burden, GRACE and SYNTAX scores are
presented in Table 3. Total residual plaque burden demonstrated a statistically significant
correlation with GRACE and SYNTAX scores (r=0.40, p=0.001 and r=0.37, p=0.004,
respectively), although there was no significant correlation between SYNTAX and GRACE
scores (r=0.20, p=0.13) (Figure 3). Figure 4 demonstrates that the proportion of patients with
total residual plaque burden above the median is higher with higher SYNTAX and GRACE
scores. Residual dense calcified plaque burden significantly correlated with GRACE and
SYNTAX scores (r=0.32, p=0.013; r=0.26, p=0.044 respectively). Residual fibrotic plaque
burden also significantly correlated with GRACE scores, although not with SYNTAX scores.
There was no statistically significant correlation between residual low attenuation plaque
burden and either the GRACE or SYNTAX scores.

Figure 2.3: Correlation of total residual plaque burden, GRACE and SYNTAX scores.
A significant correlation between total residual plaque burden and SYNTAX and GRACE scores is evident. There
is no correlation between GRACE and SYNTAX scores.

GRACE score = Global Registry of Acute Coronary Events score, SYNTAX score = Synergy between
Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery score
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Table 2.4: Correlation coefficients between parameters of residual plaque burden and GRACE and
SYNTAX scores
r

GRACE
score
SYNTAX
score
Total residual
plaque
burden
Residual low
attenuation
plaque
burden
Residual
dense
calcified
plaque
burden
Residual
fibro-fatty
plaque
burden
Residual
fibrotic
plaque
burden
Non-calcified
residual
plaque
burden

GRACE
score

SYNTAX
score

Total
residual
plaque
burden

Residual
low
attenuation
plaque
burden

Residual
dense
calcified
plaque
burden

Residual
fibrofatty
plaque
burden

Residual
fibrotic
plaque
burden

Noncalcified
residual
plaque
burden

1
0.20

1

0.40**

0.37**

1

0.18

0.14

0.46**

1

0.32*

0.26*

0.56**

0.06

1

0.061

0.19

0.36*

0.62**

-0.25

1

0.29*

0.23

0.68**

-.07

0.27*

0.00

1

0.31*

0.29*

0.84**

0.49**

0.13

0.58**

0.75**

1

Pearson correlation coefficients are displayed for normally distributed variables, Spearman correlation
coefficients are displayed for non-normally distributed variables.
*p<0.05
**p<0.01
GRACE score = Global Registry of Acute Coronary Events score, SYNTAX score = Synergy between
Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery score

48

Figure 2.4: Bar graphs depicting the relationship between GRACE and SYNTAX scores above and below
the median and the proportion of patients with total residual plaque burden above the median. It is evident
from the bar graphs, that with increasing GRACE and SYNTAX scores, an increasing proportion of patients have
a total residual plaque burden above the median.

GRACE score = Global Registry of Acute Coronary Events score, SYNTAX score = Synergy between
Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery score

Intra-observer variability
Bland-Altman analysis and scatter plots for assessing the intraobserver variability for three of
the CTCA-derived parameters of residual plaque burden are presented in Figure 5. The ICC
for intraobserver variability was 0.878 for total residual plaque burden (p<0.0001) and 0.814
for residual low attenuation plaque burden (p<0.0001), indicating good reliability (Table 4).
The ICC for intraobserver variability for residual dense calcified plaque burden demonstrated
excellent reliability at 0.942 (p<0.0001).
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Figure 5: Scatterplots for intraobserver measurements (A) and Bland-Altman plots for intraobserver
agreement (B) for parameters of residual plaque burden. Figure 4A demonstrates scatterplots with a line of
best fit (black line), 95% confidence intervals (dotted lines) and r2 values, reflecting the good reproducibility of
parameters of residual plaque burden. Figure 4B shows the mean difference of intraobserver measurements and
the limits of agreement. Intraclass correlation coefficients were 0.88 (0.48 to 0.97), 0.81 (0.01 to 0.96) and 0.94
(0.79 to 0.99) for total residual plaque burden, residual low attenuation plaque burden and residual dense calcified
plaque burden, respectively.

LAP = low attenuation plaque, DCP = dense-calcified plaque.

C. DISCUSSION
This pilot study demonstrates the feasibility of quantifying and defining the composition of
residual plaque burden using CTCA in individuals following an ACS. We found that total and
different types of plaque were associated with the GRACE and SYNTAX scores, raising the
possibility that CTCA may play a future role in predicting outcome after MACE.

CTCA-derived residual plaque burden composition in the post-ACS cohort
To the best of our knowledge, this study is the first to examine CTCA-derived residual plaque
burden composition in a cohort following an ACS. This study demonstrated a mean total
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residual plaque burden of 39%, comprised of approximately 60% fibrotic plaque, 25% fibrofatty plaque, 9% low-attenuation plaque and 6% dense-calcified plaque. These values are
consistent with those seen in previous IVUS studies evaluating residual plaque burden
composition in ACS patients, despite the fact that CTCA quantifies plaque composition across
the entire coronary tree, while IVUS only analyses the proximal components of the major
epicardial arteries. For example, using IVUS, McPherson et al. demonstrated a higher total
residual plaque burden of 49.6%, with similar plaque composition: 59% fibrotic plaque, 21%
fibrofatty plaque, 13% low-attenuation plaque and 7% dense-calcified plaque.225 These
similarities suggest that it may be sufficient to analyse plaque composition in the proximal
section of a single, major epicardial artery to obtain a representative sample of total coronary
plaque composition. Previously, CTCA-derived non-calcified (defined as any plaque <130
HU) and calcified plaque volume were evaluated in a study of 312 consecutive patients
presenting with NSTEMI who underwent CTCA prior to ICA.105 However, plaque burden and
detailed plaque characterisation (i.e. low attenuation, fibrotic, fibro-fatty plaque components)
were not reported, precluding comparison with the results of this study.

CTCA-derived residual plaque burden and risk scores
The SYNTAX score has been validated for the short- and long-term prediction of MACE in
the ACS population.158, 226 It is derived from ICA and grades luminal obstruction and lesion
complexity (including lesion calcification, location, tortuosity, presence of thrombus and
length).158 In contrast to CTCA, the SYNTAX score does not provide an estimate of plaque
within the vessel wall that does not contribute to luminal stenosis and does not evaluate plaque
composition. The present study demonstrated that CTCA-derived total residual plaque burden
is positively correlated with the SYNTAX risk score. Of the quantified plaque components,
residual dense-calcified and fibrotic plaque burden were correlated with the SYNTAX score.

51

The finding that these components were associated with the SYNTAX score is intuitive, as
fibrotic plaque burden was the parameter best correlated with total residual plaque burden,
while the SYNTAX score includes the presence of calcification in its calculation, explaining
the association with dense-calcified plaque burden. However, this study did not find evidence
of a correlation between low-attenuation plaque burden and the SYNTAX score, which is in
agreement with a previous study of 680 ACS and stable angina patients who were evaluated
with ICA, radiofrequency IVUS and near-infrared spectroscopy.227
The present study also demonstrated that residual total, dense-calcified and fibrotic
plaque burden were correlated with higher GRACE scores, whereas there was no statistically
significant association with residual low attenuation and fibro-fatty plaque burden. A metaanalysis of over 200,000 patients previously demonstrated the excellent predictivity of the
GRACE score in post-ACS patients, reporting a c-statistic of 0.82 (95% CI: 0.80-0.89) and
0.84 (95% CI: 0.82-0.87) for the prediction of MACE and mortality at short- and long-term
follow-up respectively.171 Therefore, the association between plaque burden components and
the GRACE score may suggest a possible future role for the quantification of CTCA-derived
residual plaque burden for the risk prediction of the post-ACS population. However, the
absence of an association between the GRACE score and residual low-attenuation plaque
burden differs from the findings of a recent study of stable chest pain patients from the SCOTHEART cohort, where low-attenuation plaque burden quantified on CTCA was the strongest
predictor of future MACE and mortality.58 Similar to the present study, they utilized semiautomatic plaque quantification with scan-specific thresholds for plaque components, although
low-attenuation plaque was defined differently, by a fixed threshold of <30 HU. Importantly,
this study only evaluated lower cardiovascular risk patients and did not include patients with a
history of ACS. Further research is required to delineate the most important plaque components
for defining risk in the post-ACS population.
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SYNTAX score and GRACE score
There was no significant correlation between the SYNTAX and GRACE scores in this study,
which was unexpected given that clinical determinants of cardiovascular risk (age, systolic
blood pressure and renal function) are usually at least moderately related to the extent of
atherosclerotic disease visualised on ICA. The closer relationship between CTCA-derived
residual plaque burden and the clinical risk factors comprising the GRACE score, may reflect
the capability of CTCA to quantify plaque within the vessel wall in addition to plaque causing
luminal narrowing.17 Indeed, that CTCA-derived residual plaque burden correlates with both
validated risk scores, while the risk scores do not correlate with each other, suggests that it may
have a role in the future in facilitating risk prediction for patients following an ACS.
Previous studies utilizing a variety of imaging modalities have demonstrated an
association between residual plaque burden and cardiovascular risk in the post-ACS cohort.
For example, the investigators of the PROSPECT trial demonstrated that higher residual plaque
burden (as estimated by IVUS) was associated with an increased risk of MACE.228 In another
study of 697 ACS patients who underwent successful PCI, greater IVUS-derived lesion-based
residual plaque burden was significantly associated with MACE.225 In one of the few studies
examining the prognostic value of CTCA following an ACS, residual plaque burden index was
demonstrated to be significantly associated with MACE at a median of 4.8 years of follow-up
of 169 patients.202 Residual plaque burden index was defined as total plaque volume divided
by vessel length (rather than the standard calculation of plaque burden, which divides by vessel
area instead of length), excluding stented coronary segments. Additionally, the study did not
report on the composition of quantified plaque burden or the association of different plaque
components with cardiovascular risk.
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Clinical implications
The association between CTCA-derived residual plaque burden composition and validated risk
scores observed in this study, suggests that CTCA may provide an insight into the risk profile
of individuals following an ACS event. Theoretically, the quantification of low-attenuation
plaque burden would provide the optimal evaluation of the activity and extent of coronary
atherosclerosis,44,
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although a strong relationship between this parameter and validated

clinical and angiographic risk scores was not observed in this study. Furthermore, intraobserver
variability for the measurement of residual low-attenuation plaque burden was more marked
when compared to other CTCA-derived parameters, an important consideration if this
parameter is to be utilized clinically to evaluate individual patient risk. Nonetheless, it is
possible that in the future, CTCA may improve risk stratification, allowing clinicians to target
ACS patients at the highest risk with more intense risk factor modification therapies, such as
newer blood pressure and lipid regulating therapies, or prolonged dual anti-platelet therapy.197,
229

However, further research demonstrating that CTCA incrementally improves

prognostication of the post-ACS cohort beyond that of current models is required before
integration into clinical practice.
While in this study, CTCA plaque quantification was semi-automated, recent data
demonstrates that quantification of plaque burden on CTCA can be automated, providing a
reproducible, standardised estimation of plaque burden composition that correlates well with
IVUS.218, 230 Indeed, while previously time-consuming and cumbersome to perform, continued
improvements in automation may allow for plaque burden quantification to be seamlessly
integrated into clinical practice.58
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Limitations
This study is subject to all of the limitations of a single centre, observational design.
Additionally, only a small number of patients were enrolled, and it was not powered to evaluate
hard clinical endpoints. While validated, risk scores associated with MACE and mortality (such
as the GRACE and SYNTAX scores) are imperfect substitutes for hard CVD outcomes.172, 231
Importantly, due to the absence of cardiovascular outcome data, this study was unable to
evaluate any incremental benefit of CTCA over these contemporary risk scores. Another
limitation is the quantification of plaque burden excluding stented sections (residual plaque
burden), rather than the quantification of total plaque burden prior to intervention. However,
while stented sections were excluded, plaque burden is adjusted for the area of the segment
assessed. Furthermore, it is likely that a representative sample of plaque burden composition
can be obtained through the evaluation of a representative proximal coronary segment, as
previously discussed. Additionally, several prior studies have already demonstrated the
prognostic value of the quantification of residual plaque burden following ACS.225, 228
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CHAPTER THREE: CONCLUSION AND FUTURE DIRECTIONS

The investigation of the role of CTCA in the post-ACS cohort is a highly topical field of
research, with studies such as the PREFFIR232 trial currently recruiting patients in order to
better identify those at higher risk of recurrent events. However, at this time there is insufficient
data to define the role of CTCA in the post-ACS setting. Indeed, there has been minimal
research and advances in the analysis of the post-ACS cohort with CTCA over the previous
decade. While it is less likely that improved risk stratification with CTCA will translate directly
into improved clinical outcomes as seen in lower-risk groups, the ability to more accurately
stratify the heterogeneous risk profile of the post-ACS patient group may allow for targeted
interventions for those at highest risk. For example, future trials may be able to define which
post-ACS patients should receive concurrent PCSK9 inhibitor-statin therapy or prolonged
dual-anti-platelet therapy. Introduction of CTCA as a gatekeeper to ICA in the lower-risk
NSTEMI or UA patient group could allow for integration of this theoretically improved risk
stratification (i.e. through the assessment of plaque burden and plaque composition) into
contemporary workflow whilst decreasing the rates of unnecessary ICA.
The study presented in chapter two demonstrates that total residual plaque burden and
plaque components can be quantified by CTCA after ACS and are associated with clinical and
angiographic risk scores. However, determining the clinical significance of these CTCAderived plaque components will require a large clinical study powered for hard clinical
endpoints. In addition, further studies directly comparing CTCA-derived coronary plaque
burden with conventional risk stratification models, such as the GRACE and SYNTAX scores,
are required to demonstrate any incremental benefit in prognostication for this patient group.
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